| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial | Ben Fidler | 09/18/17 | Boston |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| In New York and Montreal, Versant Seeds Two New Biotech Startups | Ben Fidler | 12/10/15 | New York |
| Avalon Debuts Three More Tiny Biotechs In Risk-Share Deal With GSK | Alex Lash | 06/15/15 | San Diego |
| East Coast Biotech Roundup: Celgene, Blueprint(s), Intarcia & More | Ben Fidler | 05/01/15 | Boston |
| West Coast Biotech Roundup: Kythera, Amgen, Otonomy, Versant & More | Alex Lash | 04/30/15 | San Diego |
| Celgene, Versant Shake Again, Cut $30M Deal For Toronto Biotech | Alex Lash | 04/29/15 | New York |
| In Venture Reinvention, Versant Sees Gains Amid Biotech Boom Times | Alex Lash | 04/29/15 | National |
| Any Given Cell: Can Biotech Pioneer Steve Fodor Do it Again? | Alex Lash | 02/13/15 | San Francisco |
| Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker | Luke Timmerman | 08/05/13 | National |
| Celgene Nabs Option to Buy Acetylon for More Than $1.7B | Ben Fidler | 07/29/13 | Boston |
| Trusting Your Partners: A Chat With Celgene’s George Golumbeski | Ben Fidler | 07/11/13 | New York |
| Forma Strikes $200M Deal With Celgene to Discover Cancer Drugs | Luke Timmerman | 04/29/13 | Boston |
| See the Agenda for ‘Reinventing Biotech’s Business Model’ Oct. 16 in SF | Luke Timmerman | 10/10/12 | San Francisco |
| See What GSK, J&J, KPCB, Third Rock & Orbimed Have in Common Oct. 16 | Luke Timmerman | 10/03/12 | San Francisco |
| Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire | Luke Timmerman | 11/04/11 | San Francisco |
